Savara stock gets USD 12 JPMorgan target before FDA date

Published on 10/08/2026 at 06:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Savara stock drew a USD 12.00 JPMorgan target on October 7, 2026. Its latest quarterly EPS was USD -0.16 versus USD -0.14 consensus.

SVRA, US8051111016, Illustration mit AI erstellt.

Savara stock (ISIN US8051111016) was last at USD 4.9850 on NASDAQ on October 7, 2026, after a 7.2 percent intraday gain. MarketBeat reported on October 7, 2026, that JPMorgan initiated coverage with an Overweight rating and a USD 12.00 price target.

JPMorgan sets a USD 12 target

The JPMorgan target stands above the current quote, but the wider analyst picture remains mixed. MarketBeat listed one Strong Buy, seven Buy and one Sell rating, producing a Moderate Buy consensus and an average price target of USD 10.25.

That average target lies 105.6 percent above the USD 4.9850 price. The comparison matters because the target reflects expectations around Savara's lead respiratory program rather than current product revenue.

FDA decision sets the next test

Investing.com reported on October 7, 2026, that Citizens maintained a Market Outperform rating and a USD 10.00 price target. The report identified November 22, 2026, as the PDUFA date for Molbreevi, Savara's molgramostim treatment for autoimmune pulmonary alveolar proteinosis.

RTTNews also listed November 22, 2026, as the event date. The regulatory decision is therefore the next company-specific checkpoint behind the analyst targets.

Quarterly loss remains a counterweight

Savara's latest reported quarter produced EPS of USD -0.16, missing the USD -0.14 consensus estimate by USD 0.02, according to MarketBeat in its October 7, 2026 report. Savara remains a clinical-stage biotechnology company whose lead candidate is inhaled molgramostim.

SVRA remains below its yearly high

SVRA traded between USD 3.34 and USD 7.01 over the prior 52 weeks, while its market capitalization was USD 1.03 billion on October 7, 2026. The stock's 7.2 percent session gain brought the quote closer to the middle of that yearly range, but the November decision remains the central event for the valuation case.